Across TCGA pan-cancer cohorts, IGHV1-2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of IGHV1-2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where IGHV1-2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types IGHV1-2 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where IGHV1-2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGHV1-2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	−0.682	<.001	8	view →
LUAD	Female	All	−0.566	<.001	6	view →
LSCC	Male	All	−0.347	<.001	4	view →
CCRCC	All	All	+0.361	.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: IGHV1-2 RNA expression & survival · all IGHV1-2 data types